The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Research works printed but not linked: 21
- Jacobs, 2000, Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group, N Engl J Med, 343, 898, 10.1056/NEJM200009283431301 · DOI · Paper page
- Comi, 2001, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, Lancet, 357, 1576, 10.1016/S0140-6736(00)04725-5 · DOI · Paper page
- Kappos, 2006, Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, 67, 1242, 10.1212/01.wnl.0000237641.33768.8d · DOI · Paper page
- Poser, 1983, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, 13, 227, 10.1002/ana.410130302 · DOI · Paper page
- Kuhlmann, 2002, Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time, Brain, 125, 2202, 10.1093/brain/awf235 · DOI · Paper page
- Barnett, 2004, Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion, Ann Neurol, 55, 458, 10.1002/ana.20016 · DOI · Paper page
- Cutter, 1999, Development of a multiple sclerosis functional composite as a clinical trial outcome measure, Brain, 122, 871, 10.1093/brain/122.5.871 · DOI · Paper page
- Cella, 1996, Validation of the functional assessment of multiple sclerosis quality of life instrument, Neurology, 47, 129, 10.1212/WNL.47.1.129 · DOI · Paper page
- Pungor, 1998, A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b, J Interferon Cytokine Res, 18, 1025, 10.1089/jir.1998.18.1025 · doi:10.1089/jir.1998.18.1025
- Sidak, 1967, Rectangular confidence region for the means of multivariate normal distributions, J Am Stat Assoc, 62, 626
- McDonald, 2001, Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, 50, 121, 10.1002/ana.1032 · DOI · Paper page
- Smith, 2002, Accurate, robust, and automated longitudinal and cross-sectional brain change analysis, Neuroimage, 17, 479, 10.1006/nimg.2002.1040 · DOI · Paper page
- Filippi, 2003, Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis, Brain, 126, 433, 10.1093/brain/awg038 · DOI · Paper page
- Pantano, 2002, Cortical motor reorganization after a single clinical attack of multiple sclerosis, Brain, 125, 1607, 10.1093/brain/awf164 · DOI · Paper page
- Lublin, 2003, Effect of relapses on development of residual deficit in multiple sclerosis, Neurology, 61, 1528, 10.1212/01.WNL.0000096175.39831.21 · DOI · Paper page
- Kinkel, 2006, IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event, Neurology, 66, 678, 10.1212/01.wnl.0000200778.65597.ae · DOI · Paper page
- Rio, 2006, Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients, Ann Neurol, 59, 344, 10.1002/ana.20740 · DOI · Paper page
- 2001, PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS, Neurology, 56, 1628, 10.1212/WNL.56.12.1628 · DOI · Paper page
- Hoogervorst, 2001, Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis, Mult Scler, 7, 335, 10.1177/135245850100700510 · DOI
- Cutter, 1999, Development of a multiple sclerosis functional composite as a clinical trial outcome measure, Brain, 122, 871, 10.1093/brain/122.5.871 · DOI · Paper page
- Paty, 1993, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group, Neurology, 43, 662, 10.1212/WNL.43.4.662 · DOI · Paper page
Cited by
Efficient multi-scale 3D CNN with fully connected CRF for accurate brain lesion segmentation
Kamnitsas, K., Ledig, C., Newcombe, V. F. J., Simpson, J. P., Kane, A. D., Menon, D. K., Rueckert, D., & Glocker, B. (2017) · Medical Image Analysis · doi:10.1016/j.media.2016.10.004 · Cited by 3,498
“In clinical research on multiple sclerosis (MS), lesion count and volume are used to analyse disease progression and effectiveness of pharmaceutical treatment (Rovira and León (2008); Kappos et al. (2007)).”
BackgroundCohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Self-citationFisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
Self-citationHobart, J. C., Cano, S. J., Zajicek, J. P., & Thompson, A. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70290-9 · Cited by 495
Vitamin D and Multiple Sclerosis: A Comprehensive Review
Sintzel, M. B., Rametta, M., & Reder, A. T. (2018) · Neurology and Therapy · doi:10.1007/s40120-017-0086-4 · Cited by 435
Metadata
- Authors
- Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H.-P., Miller, D. H., Montalbán, X., Barkhof, F., Radü, E.-W., Bauer, L., Dahms, S., Lanius, V., Pohl, C., & Sandbrink, R.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2007-08
- Volume
- 370
- Issue
- 9585
- Pages
- 389-397
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2146802292
- Cited by
- 502
- References
- 3
- FWCI
- 32.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Bayer Schering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. https://app.cochat.ai/papers/10.1016/s0140-6736(07)61194-5
- The paper
- Kappos, L., Freedman, M. S., Polman, C. H., Edan, G., Hartung, H.-P., Miller, D. H., Montalbán, X., Barkhof, F., Radü, E.-W., Bauer, L., Dahms, S., Lanius, V., Pohl, C., & Sandbrink, R. (2007). Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. The Lancet. https://doi.org/10.1016/s0140-6736(07)61194-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
